Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases.

Evans AT, Loeb KR, Shulman HM, Hassan S, Qiu WC, Hockenbery DM, Ioannou GN, Chauncey TR, Gretch DR, McDonald GB.

Am J Surg Pathol. 2015 Feb;39(2):212-20. doi: 10.1097/PAS.0000000000000345.

PMID:
25517948
2.

Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection.

Livingston SE, Townshend-Bulson LJ, Bruden DL, McMahon BJ, Homan CE, Gove JE, Deubner H, Bruce MG, Robinson RF, Gretch DR.

Int J Circumpolar Health. 2012 Apr 24;71:1-7. doi: 10.3402/ijch.v71i0.18445.

3.

Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infection.

Li H, Atkins E, Bruckner J, McArdle S, Qiu WC, Thomassen LV, Scott J, Shuhart MC, Livingston S, Townshend-Bulson L, McMahon BJ, Harris M, Griffin S, Gretch DR.

Virology. 2012 Feb 5;423(1):30-7. doi: 10.1016/j.virol.2011.11.011. Epub 2011 Dec 14.

4.

Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time.

Li H, Hughes AL, Bano N, McArdle S, Livingston S, Deubner H, McMahon BJ, Townshend-Bulson L, McMahan R, Rosen HR, Gretch DR.

PLoS One. 2011 May 5;6(5):e19562. doi: 10.1371/journal.pone.0019562.

5.

Use of the AST to platelet ratio index in HCV/HIV co-infected patients.

Singal AG, Thomassen LV, Gretch DR, Shuhart MC.

Aliment Pharmacol Ther. 2011 Mar;33(5):566-77. doi: 10.1111/j.1365-2036.2010.04560.x. Epub 2011 Jan 5.

6.

Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.

McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, Gretch DR, Rosen HR.

J Clin Invest. 2010 Dec;120(12):4546-57. doi: 10.1172/JCI43127. Epub 2010 Nov 15. Erratum in: J Clin Invest. 2011 Feb 1;121(2):821.

7.

Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C.

Livingston SE, Deubner H, Bruden DL, McMahon BJ, Homan CE, Townshend-Bulson LJ, Bruce MG, Hennessy TW, Williams JL, Gretch DR.

Can J Gastroenterol. 2010 Jul;24(7):445-51.

8.

Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation.

Li H, Sullivan DG, Feuerborn N, McArdle S, Bekele K, Pal S, Yeh M, Carithers RL, Perkins JD, Gretch DR.

Virology. 2010 Jul 5;402(2):248-55. doi: 10.1016/j.virol.2010.03.040. Epub 2010 Apr 18.

9.

Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1.

Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A.

J Gastroenterol Hepatol. 2010 Mar;25(3):627-34. doi: 10.1111/j.1440-1746.2009.06128.x. Epub 2010 Jan 14.

10.

Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, Castelblanco N, Kuchroo V, Gretch DR, Rosen HR.

J Virol. 2009 Sep;83(18):9122-30. doi: 10.1128/JVI.00639-09. Epub 2009 Jul 8.

11.

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877.

12.

Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.

Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM; HALT-C Trial Group.

Hepatology. 2008 Nov;48(5):1412-9. doi: 10.1002/hep.22487.

13.

Investigation of putative multisubtype hepatitis C virus infections in vivo by heteroduplex mobility analysis of core/envelope subgenomes.

Li H, Thomassen LV, Majid A, McMahon BJ, Bruden D, McArdle S, Bano N, Chung M, Carithers RL, Perkins JD, Sullivan DG, Gretch DR.

J Virol. 2008 Aug;82(15):7524-32. doi: 10.1128/JVI.02220-07. Epub 2008 May 21.

14.

Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, Shelton D, Deubner H, Gretch DR.

Virology. 2008 Jun 5;375(2):580-91. doi: 10.1016/j.virol.2008.02.012. Epub 2008 Mar 17.

15.

Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection.

Morishima C, Shuhart MC, Yoshihara CS, Paschal DM, Silva MA, Thomassen LV, Emerson SS, Gretch DR.

J Infect Dis. 2007 Aug 15;196(4):577-86. Epub 2007 Jun 28.

PMID:
17624844
16.

Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease.

Sullivan DG, Bruden D, Deubner H, McArdle S, Chung M, Christensen C, Hennessy T, Homan C, Williams J, McMahon BJ, Gretch DR.

J Infect Dis. 2007 Jul 15;196(2):239-48. Epub 2007 Jun 7.

PMID:
17570111
17.

Molecular diagnostics of hepatitis C virus infection: a systematic review.

Scott JD, Gretch DR.

JAMA. 2007 Feb 21;297(7):724-32. Review.

PMID:
17312292
18.

Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes.

Lázaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, Corey L, Coombs RW, Fausto N.

Am J Pathol. 2007 Feb;170(2):478-89.

19.

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR.

Gastroenterology. 2007 Jan;132(1):103-12. Epub 2006 Nov 11.

PMID:
17241864
20.

Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR; HALT-C Trial Group.

J Hepatol. 2007 Mar;46(3):420-31. Epub 2006 Nov 27.

21.

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.

Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, Halt-C Trial Group.

Gastrointest Endosc. 2006 Dec;64(6):855-64.

PMID:
17140886
22.

Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors.

Brewer DD, Hagan H, Sullivan DG, Muth SQ, Hough ES, Feuerborn NA, Gretch DR.

J Infect Dis. 2006 Sep 15;194(6):764-72. Epub 2006 Aug 17.

PMID:
16941342
23.

Steatosis and hepatitis C in an Alaska Native/American Indian population.

Livingston SE, Deubner H, McMahon BJ, Bruden D, Christensen C, Hennessy TW, Bruce MG, Sullivan DG, Homan C, Williams J, Gretch DR.

Int J Circumpolar Health. 2006 Jun;65(3):253-60.

PMID:
16871831
24.

HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.

Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR; HALT-C Trial Group.

Hepatology. 2006 Aug;44(2):360-7.

PMID:
16871570
25.

Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism.

Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, Carithers RL Jr, Wood BL, Perkins JD, Gretch DR.

Gastroenterology. 2006 Apr;130(4):1107-16.

PMID:
16618405
26.

HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability.

Shuhart MC, Sullivan DG, Bekele K, Harrington RD, Kitahata MM, Mathisen TL, Thomassen LV, Emerson SS, Gretch DR.

J Infect Dis. 2006 May 1;193(9):1211-8. Epub 2006 Mar 28.

PMID:
16586356
27.

Identification of a specific gene expression pattern associated with HCV-induced pathogenesis in HCV- and HCV/HIV-infected individuals.

Walters KA, Smith MW, Pal S, Thompson JC, Thomas MJ, Yeh MM, Thomas DL, Fitzgibbon M, Proll S, Fausto N, Gretch DR, Carithers RL Jr, Shuhart MC, Katze MG.

Virology. 2006 Jul 5;350(2):453-64. Epub 2006 Mar 30.

28.

Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.

Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR; HALT-C Trial Group.

Am J Gastroenterol. 2006 May;101(5):983-92.

29.

Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.

J Infect Dis. 2006 Apr 1;193(7):931-40. Epub 2006 Feb 22.

PMID:
16518754
30.

High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives.

Scott JD, McMahon BJ, Bruden D, Sullivan D, Homan C, Christensen C, Gretch DR.

Clin Infect Dis. 2006 Apr 1;42(7):945-52. Epub 2006 Feb 28.

PMID:
16511757
31.

Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.

Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, Emerson SS, Shuhart MC, Gretch DR.

Hepatology. 2006 Mar;43(3):573-80.

PMID:
16496327
32.

Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo.

Pal S, Shuhart MC, Thomassen L, Emerson SS, Su T, Feuerborn N, Kae J, Gretch DR.

J Virol. 2006 Mar;80(5):2280-90.

33.

High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection.

Wang CC, Morishima C, Chung M, Engelberg R, Krantz E, Krows M, Sullivan DG, Gretch DR, Corey L.

J Infect Dis. 2006 Mar 1;193(5):672-6. Epub 2006 Jan 27.

PMID:
16453262
34.

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR; HALT-C Trial Group.

J Hepatol. 2005 Sep;43(3):434-41.

PMID:
16136646
35.

Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.

Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR; HALT-C Trial Group.

Virol J. 2005 Apr 22;2:41.

36.

Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.

Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ; HALT-C Trial Group.

Hepatology. 2005 Mar;41(3):617-25.

PMID:
15726656
37.

Laboratory approaches to the diagnosis of hepatitis C virus infection.

Jerome KR, Gretch DR.

Minerva Gastroenterol Dietol. 2004 Mar;50(1):9-20. Review.

PMID:
15719002
38.

Use and interpretation of HCV diagnostic tests in the clinical setting.

Gretch DR.

Clin Liver Dis. 1997 Nov;1(3):543-57, vi. Review.

PMID:
15560057
39.

Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera.

Bruden DL, McMahon BJ, Hennessy TW, Christensen CJ, Homan CE, Williams JL, Sullivan DG, Gretch DR, Cagle HH, Bulkow LR.

Am J Gastroenterol. 2004 Aug;99(8):1517-22.

PMID:
15307870
40.

Effects of the hepatitis C virus core protein on innate cellular defense pathways.

Miller K, McArdle S, Gale MJ Jr, Geller DA, Tenoever B, Hiscott J, Gretch DR, Polyak SJ.

J Interferon Cytokine Res. 2004 Jul;24(7):391-402.

PMID:
15296650
41.
42.

Epidemiology and risk factors for hepatitis C in Alaska Natives.

McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, Deubner H, Bruce MG, Livingston S, Williams J, Gretch DR.

Hepatology. 2004 Feb;39(2):325-32.

PMID:
14767985
43.

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR.

J Clin Microbiol. 2004 Jan;42(1):421-5.

44.

Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.

Morishima C, Musey L, Elizaga M, Gaba K, Allison M, Carithers RL, Gretch DR, McElrath MJ.

Clin Immunol. 2003 Sep;108(3):211-20.

PMID:
14499244
45.

Comparison of different HCV viral load and genotyping assays.

Anderson JC, Simonetti J, Fisher DG, Williams J, Yamamura Y, Rodriguez N, Sullivan DG, Gretch DR, McMahon B, Williams KJ.

J Clin Virol. 2003 Sep;28(1):27-37.

PMID:
12927748
46.

Dynamics of hepatitis C virus replication in human liver.

Chang M, Williams O, Mittler J, Quintanilla A, Carithers RL Jr, Perkins J, Corey L, Gretch DR.

Am J Pathol. 2003 Aug;163(2):433-44.

47.

Hepatitis C and alcohol: fundamental and translational research directions.

Morgan TR, Brenner D, Everhart J, French SW, Fried MW, Gretch DR, Koziel MJ, McClain CJ, Peters MG, Weinman SA, Lucas DL.

Alcohol Clin Exp Res. 2003 Apr;27(4):726-31. Review.

PMID:
12711937
48.

Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study.

Murray KF, Richardson LP, Morishima C, Owens JW, Gretch DR.

Pediatrics. 2003 Jan;111(1):153-7.

PMID:
12509569
49.

Current and future hepatitis C virus diagnostic testing: problems and advancements.

Majid AM, Gretch DR.

Microbes Infect. 2002 Oct;4(12):1227-36. Review.

PMID:
12467764
50.

Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy.

Rosen HR, Ribeiro RR, Weinberger L, Wolf S, Chung M, Gretch DR, Perelson AS.

J Hepatol. 2002 Jul;37(1):124-30.

PMID:
12076871

Supplemental Content

Loading ...
Support Center